Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The OptiTROP-Breast01 study demonstrates that sacituzumab tirumotecan monotherapy shows benefits in PFS and OS compared to chemotherapy in advanced TNBC
Warning: If you are pregnant or lactating, have any health condition or are taking any medication, consult your health professional before use
Limitations of Current Evidence The absence of large-scale human clinical trials represents the primary evidence gap
Intermediate phase (weeks 5-8) This is when body composition changes typically become noticeable
US$ 20.58
US$ 24.36
US$ 21.07
US$ 26.23
US$ 26.24
